Fresenius | FRE - Selling And Administration Expenses


Fresenius reported EUR819M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Akzo Nobel EUR 804M 7M Mar/2026
Alcon AG USD 882M 19M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
BASF EUR 2.13B 84M Mar/2026
Bayer EUR 3.7B 356M Mar/2026
Beiersdorf EUR 271M 51M Dec/2025
DaVita Healthcare Partners USD 421.91M 50.45M Mar/2026
Demant DKK 6.09B 135M Dec/2025
E.ON EUR -1.71B 3.63B Jun/2025
Essilor EUR 5.62B 4.53B Dec/2025
Fresenius EUR 819M 143M Dec/2025
Fresenius Medical Care EUR 749M 36M Mar/2026
Getinge SEK 2.65B 452M Dec/2024
Givaudan CHF 561M 25M Dec/2025
GlaxoSmithKline GBP 2.12B 558M Mar/2026
GN Store Nord DKK 763M 688M Mar/2026
GRIFOLS EUR 281M 5.7M Mar/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Merck EUR 1.52B 80M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Philips EUR 1.18B 121M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
RWE EUR 690M 84M Mar/2025
Sanofi EUR 2.33B 419M Mar/2026
Smith & Nephew USD 1.42B 65M Dec/2025